CD103 Antibody [2E7] (FITC) | 98-975

CD103 Antibody [2E7] (FITC) | 98-975 | Gentaur UK, US & Europe Distribution

Host: Hamster

Reactivity: Mouse

Homology: N/A

Immunogen: C57BL/6J mouse intestinal intraepithelial lymphocytes (IEL)

Research Area: Immunology, Stem Cell, Signal Transduction

Tested Application: Flow

Application: CD103 Antibody [2E7] for use in flow cytometry and immunohistochemistry assays.

Specificiy: CD103

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: N/A

Clonality: Monoclonal

Clone: [2E7]

Isotype: IgG

Conjugate: FITC

Physical State: Liquid

Buffer: Supplied in PBS/NaN3

Concentration: 0.5 mg/mL

Storage Condition: Store vial at 2-8˚C

Alternate Name: Integrin alphaIEL, alphaE integrin, ITGAE

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: CD103 is a member of the integrin series of adhesion molecules. This antigen defines a developmentally important subset of T cells, namely mucosal T cells including all IEL (intraepithelial lymphocytes) and ~20% of lamina propria T cells. Expression of CD103 is more restricted outside these mucosal organs appearing at lower levels on T cell subsets of the lymph node, dendritic epidermis, and periphery. In non-epithelial CD103+ T cells there is a bias toward expression on CD8+ cells. The 2E7 monoclonal antibody exhibits antigen immunoprecipitation patterns similar if not identical to the rat anti-mouse CD103 monoclonal antibody M290. 2E7 is reported to have signal-inducing activity in a redirected lysis assay and to costimulate IEL and CD8+ lymph node cells in conjunction with anti-TCR in vitro which runs counter to the usual inhibition of CTL by anti-integrins. This costimulatory activity is also shared by the monoclonal antibody M290. The property of costimulation is not unique to the mouse since the combination of anti-human alphaIEL plus anti-TCR will produce similar proliferation in human cells with the exception that CD8+ cells are not stimulated.